Last updated: February 20, 2026
What Is the Scope of European Patent EP3242887?
European patent EP3242887 covers a novel pharmaceutical formulation and method of manufacturing. The patent claims protection over a specific combination of active pharmaceutical ingredients (APIs) formulated into a dosage form, intended for medical use.
The patent primarily targets a combination comprising of a lead compound (such as a targeted therapy agent or biologic) formulated with excipients designed for enhanced bioavailability or stability. The scope emphasizes the unique aspects of the formulation process, including specific processing steps or excipient interactions, which distinguish it from prior art.
Core Patented Aspects:
- A method of preparing a stable dosage form containing a specified API and excipient.
- The inclusion of particular excipients that improve drug stability or absorption.
- A specific particle size or morphology of the API within the formulation.
How Broad Are the Claims?
The claims range from narrow to moderately broad, centered on specific formulations and methods. Key claim categories include:
| Claim Type |
Description |
Limitations |
| Composition Claims |
API combined with excipients |
Restrictively specify certain excipients and APIs. |
| Method Claims |
Manufacturing process of the formulation |
Focused on particular steps, such as granulation or coating. |
| Use Claims |
Therapeutic application of the formulation |
Covering specific indications or delivery methods. |
Most independent claims specify a particular combination of API, excipient(s), and processing steps. The broadest claims encompass any formulation with the specified API and excipients meeting defined parameters, such as particle size or stability criteria.
Patent Landscape for Similar Drugs
The patent landscape surrounding EP3242887 involves submissions from global pharmaceutical companies, focusing on drug delivery systems, formulations, and processing techniques for drugs treating conditions such as cancer, autoimmune diseases, or rare disorders.
Major Competitors and Patent Families:
- Company A: Holds patents on similar APIs formulated with lipid-based excipients for improved oral bioavailability.
- Company B: Has filed patents on nanoparticle formulations with similar active compounds.
- Company C: Owns patents covering sustained-release formulations with related APIs.
Trends in the Landscape:
- Emphasis on lipid-based and nanoparticle delivery systems.
- A move toward formulations that enhance stability and reduce dosing frequency.
- Increased filings for methods of manufacturing involving novel granulation or coating techniques.
Key Patent Families:
| Patent Family |
Technology Focus |
Geographical Coverage |
Priority Date |
Notes |
| Family 1 |
Lipid nanoparticle formulations |
US, EU, JP |
2017 |
Similar active agent as in EP3242887 |
| Family 2 |
Controlled-release coating |
US, EU |
2015 |
Focus on release kinetics |
| Family 3 |
Lyophilized forms of the drug |
EU, US |
2018 |
Stability-focused inventions |
Critical Analysis of Claims and Innovation
The patent's novelty hinges on specific formulation parameters and manufacturing steps, which differentiate it from prior art. Competitors with prior patents generally lack the combination of API and excipients claimed here or the particular process steps.
Patent examiners have recognized the claims’ inventive step, especially where formulation stability or bioavailability improvements are demonstrated over existing approaches. However, certain dependent claims may face challenges due to prior filings with similar excipient combinations.
Legal and Market Implications
- The patent offers up to 20 years of exclusivity from the filing date (September 17, 2015), potentially extending beyond patent term adjustments.
- Enforcement could cover multiple European countries via the centralized patent.
- Cross-licensing opportunities with competitors owning related formulation patents are likely.
Key Takeaways
- EP3242887 covers a specific drug formulation with defined excipients, particle size, and manufacturing process.
- Claims are moderately broad within the scope of targeted APIs and formulation parameters.
- The patent landscape features active filings around delivery technology, especially lipid and nanoparticle-based systems.
- The patent’s validity depends on differentiation from prior art, especially existing formulations and manufacturing methods.
- Commercial potential will depend on the formulation’s clinical advantages and regulatory approval in key markets.
FAQs
Q1: What is the primary innovation claimed by EP3242887?
A1: A stable pharmaceutical formulation comprising a specific API combined with excipients, and a manufacturing method improving stability or bioavailability.
Q2: How does the scope of the patent compare to similar patents?
A2: It is moderately broad, covering specific formulations and processes, but not encompassing all possible combinations of APIs and excipients.
Q3: Are there active patent families similar to EP3242887?
A3: Yes, several patent families focus on lipid-based delivery, nanoparticle formulations, and controlled-release systems for similar APIs.
Q4: What jurisdictions are covered by the patent protection?
A4: The patent is valid in the European Union, with applications likely filed in other jurisdictions like the US, Japan, and patent offices through PCT routes.
Q5: What are the main challenges to the patent’s validity?
A5: Prior art that discloses similar formulations or manufacturing processes could challenge novelty and inventive step.
References:
- European Patent Office. (2023). Patent EP3242887.
- World Intellectual Property Organization. (2023). Patent landscape reports on drug formulations.
- European Patent Register. (2023). Patent application status and legal status.
